Zobrazeno 1 - 10 of 44 pro vyhledávání: '"Nagasawa JY"'
1
Akademický článek
Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.
Autor: Govek SP; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States. Electronic address: sgovek@san.rr.com., Bonnefous C; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Julien JD; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Nagasawa JY; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Kahraman M; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Lai AG; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Douglas KL; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Aparicio AM; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Darimont BD; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Grillot KL; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Joseph JD; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Kaufman JA; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Lee KJ; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Lu N; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Moon MJ; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Prudente RY; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Sensintaffar J; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Rix PJ; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Hager JH; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Smith ND; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States.
Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2019 Feb 01; Vol. 29 (3), pp. 367-372. Date of Electronic Publication: 2018 Dec 19.
Zobrazit plný text záznamu
3
Akademický článek
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.
Autor: Kahraman M; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Govek SP; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Nagasawa JY; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Lai A; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Bonnefous C; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Douglas K; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Sensintaffar J; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Liu N; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Lee K; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Aparicio A; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Kaufman J; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Qian J; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Shao G; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Prudente R; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Joseph JD; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Darimont B; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Brigham D; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Heyman R; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Rix PJ; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Hager JH; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States., Smith ND; Department of Chemistry, Department of Biology, and Department of Drug Safety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States.
Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2018 Dec 06; Vol. 10 (1), pp. 50-55. Date of Electronic Publication: 2018 Dec 06 (Print Publication: 2019).
Zobrazit plný text záznamu
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.
Autor: Joseph JD; Department of Biology, Seragon Pharmaceuticals, San Diego, United States., Darimont B; Department of Biology, Seragon Pharmaceuticals, San Diego, United States., Zhou W; Department of Translational Oncology, Genentech, South San Francisco, United States., Arrazate A; Department of Translational Oncology, Genentech, South San Francisco, United States., Young A; Department of Translational Oncology, Genentech, South San Francisco, United States., Ingalla E; Department of Translational Oncology, Genentech, South San Francisco, United States., Walter K; Department of Oncology Biomarker Development, Genentech, South San Francisco, United States., Blake RA; Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, United States., Nonomiya J; Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, United States., Guan Z; Department of Translational Oncology, Genentech, South San Francisco, United States., Kategaya L; Departments of Discovery Oncology and Early Discovery Biochemistry, Genentech, South San Francisco, United States., Govek SP; Department of Chemistry, Seragon Pharmaceuticals, San Diego, United States., Lai AG; Department of Chemistry, Seragon Pharmaceuticals, San Diego, United States., Kahraman M; Department of Chemistry, Seragon Pharmaceuticals, San Diego, United States., Brigham D; Department of Biology, Seragon Pharmaceuticals, San Diego, United States., Sensintaffar J; Department of Biology, Seragon Pharmaceuticals, San Diego, United States., Lu N; Department of Biology, Seragon Pharmaceuticals, San Diego, United States., Shao G; Department of Biology, Seragon Pharmaceuticals, San Diego, United States., Qian J; Department of Biology, Seragon Pharmaceuticals, San Diego, United States., Grillot K; Department of Biology, Seragon Pharmaceuticals, San Diego, United States., Moon M; Department of Biology, Seragon Pharmaceuticals, San Diego, United States., Prudente R; Department of Biology, Seragon Pharmaceuticals, San Diego, United States., Bischoff E; Department of Biology, Seragon Pharmaceuticals, San Diego, United States., Lee KJ; Department of Drug Safety and Disposition, Seragon Pharmaceuticals, San Diego, United States., Bonnefous C; Department of Chemistry, Seragon Pharmaceuticals, San Diego, United States., Douglas KL; Department of Chemistry, Seragon Pharmaceuticals, San Diego, United States., Julien JD; Department of Chemistry, Seragon Pharmaceuticals, San Diego, United States., Nagasawa JY; Department of Chemistry, Seragon Pharmaceuticals, San Diego, United States., Aparicio A; Department of Drug Safety and Disposition, Seragon Pharmaceuticals, San Diego, United States., Kaufman J; Department of Drug Safety and Disposition, Seragon Pharmaceuticals, San Diego, United States., Haley B; Department of Molecular Biology, Genentech, South San Francisco, United States., Giltnane JM; Department of Pathology, Genentech, South San Francisco, United States., Wertz IE; Departments of Discovery Oncology and Early Discovery Biochemistry, Genentech, South San Francisco, United States., Lackner MR; Department of Oncology Biomarker Development, Genentech, South San Francisco, United States., Nannini MA; Department of Translational Oncology, Genentech, South San Francisco, United States., Sampath D; Department of Translational Oncology, Genentech, South San Francisco, United States., Schwarz L; Department of Medicine and Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Nashville, United States., Manning HC; Vanderbilt University Institute of Imaging Science, Vanderbilt University, Nashville, United States., Tantawy MN; Vanderbilt University Institute of Imaging Science, Vanderbilt University, Nashville, United States., Arteaga CL; Department of Medicine and Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Nashville, United States., Heyman RA; Department of Biology, Seragon Pharmaceuticals, San Diego, United States., Rix PJ; Department of Drug Safety and Disposition, Seragon Pharmaceuticals, San Diego, United States., Friedman L; Department of Translational Oncology, Genentech, South San Francisco, United States., Smith ND; Department of Chemistry, Seragon Pharmaceuticals, San Diego, United States., Metcalfe C; Department of Translational Oncology, Genentech, South San Francisco, United States., Hager JH; Department of Biology, Seragon Pharmaceuticals, San Diego, United States.
Publikováno v: ELife [Elife] 2016 Jul 13; Vol. 5. Date of Electronic Publication: 2016 Jul 13.
Zobrazit plný text záznamu
7
Akademický článek
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.
Autor: Govek SP; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States. Electronic address: sgovek@seragonpharm.com., Nagasawa JY; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Douglas KL; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Lai AG; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Kahraman M; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Bonnefous C; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Aparicio AM; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Darimont BD; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Grillot KL; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Joseph JD; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Kaufman JA; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Lee KJ; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Lu N; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Moon MJ; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Prudente RY; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Sensintaffar J; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Rix PJ; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Hager JH; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States., Smith ND; Seragon Pharmaceuticals, Inc., 12780 El Camino Real, Suite 302, San Diego, CA 92130, United States.
Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2015 Nov 15; Vol. 25 (22), pp. 5163-7. Date of Electronic Publication: 2015 Oct 03.
Zobrazit plný text záznamu
8
Akademický článek
Selective Estrogen Receptor Degraders (SERDs).
Autor: Taylor, Melissa, Kahn, Adriana, Foldi, Julia
Publikováno v: Current Breast Cancer Reports; Dec2024, Vol. 16 Issue 4, p402-416, 15p
Zobrazit plný text záznamu
10
Akademický článek
6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4-dihydroquinolines as HIV integrase inhibitors.
Autor: Nagasawa JY; Department of Discovery Chemistry, Ardea Biosciences, Inc., 4939 Directors Place, San Diego, CA 92121, USA., Song J, Chen H, Kim HW, Blazel J, Ouk S, Groschel B, Borges V, Ong V, Yeh LT, Girardet JL, Vernier JM, Raney AK, Pinkerton AB
Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2011 Jan 15; Vol. 21 (2), pp. 760-3. Date of Electronic Publication: 2010 Nov 30.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje